Company Overview of ZEDIRA GmbH
ZEDIRA GmbH, a biopharmaceutical company, develops drugs to treat celiac disease. It offers TG6, a neuronal transglutaminase marker used in detecting neurological disorders caused by gluten. The company also produces and markets specialty reagents to assist investigators who are studying celiac disease; and develops active ingredients and celiac disease diagnostic antigens. ZEDIRA GmbH also provides proteases, assays, substrates, antibodies, inhibitors, and autoantibody detection ELISA-Kits. The company was founded in 2007 and is based in Darmstadt, Germany.
Founded in 2007
49 6151 3251-00
49 6151 3251-19
Key Executives for ZEDIRA GmbH
Similar Private Companies By Industry
|3B Pharmaceuticals GmbH||Europe|
|Accelsiors Group International||Europe|
|Aenova Group GmbH||Europe|
|Aenova Holding GmbH||Europe|
|AiCuris GmbH & Co. KG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ZEDIRA GmbH, please visit www.zedira.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.